Pharma Mar (OTCMKTS:PHMMF) Short Interest Update

Pharma Mar (OTCMKTS:PHMMF) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 8,682 shares, a growth of 9,136.2% from the August 15th total of 94 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 36 shares, the short-interest ratio is currently 241.2 days.

Pharma Mar Price Performance

Shares of OTCMKTS PHMMF remained flat at $94.60 during midday trading on Thursday. 3 shares of the stock were exchanged, compared to its average volume of 20. The firm has a fifty day simple moving average of $88.37 and a 200 day simple moving average of $93.91. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.44 and a current ratio of 3.02. Pharma Mar has a 1 year low of $77.41 and a 1 year high of $110.40.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Zacks Research raised shares of Pharma Mar to a “hold” rating in a research note on Monday, June 15th. Chardan Capital raised Pharma Mar to a “strong-buy” rating in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy”.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.